ACNs disrupt this balance by enhancing ROS production (e.g., activating NADPH oxidase or causing mitochondrial dysfunction) while simultaneously inhibiting the antioxidant defense mechanisms of tumor cells. This evidence concerns the gene FMO5 and neoplasm.